# Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

> **NCT05433285** · PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 4050 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** COVID-19 Protein Subunit Recombinant Vaccine
- **BIOLOGICAL:** Active Comparator

## Key facts

- **NCT ID:** NCT05433285
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-07
- **Primary completion:** 2022-08-05
- **Final completion:** 2023-08-31
- **Target enrollment:** 4050 (ACTUAL)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433285, "Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05433285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*